{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"BioSig Technologies, Inc."},"Symbol":{"label":"Symbol","value":"BSGM"},"Address":{"label":"Address","value":"54 WILTON ROAD,2ND FLOOR, WESTPORT, Connecticut, 06880, United States"},"Phone":{"label":"Phone","value":"+1 203 409-5444"},"Industry":{"label":"Industry","value":"Biotechnology: Electromedical & Electrotherapeutic Apparatus"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"BioSig Technologies is an advanced medical technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), BioSig is committed to addressing healthcare's biggest priorities-saving time, saving costs, and saving lives. The Company's first product, the PURE EP System, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform insight-based, highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy. The global EP market is projected to reach $16B in 2028 with an 11.2% growth rate."},"CompanyUrl":{"label":"Company Url","value":"https://www.biosig.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Anthony Amato","title":"Chairman, President & Chief Executive Officer"},{"name":"Budimir S. Drakulic","title":"Chief Technology Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}